Menu Back to Poster-Presentations-Details
W 42: Adaptive Design in Dose Selection Study of Next-in-Class NNRTI
- IPHARMA LLC
Randomized clinical trial of VM-1500 was conducted at 13 Russian sites. VM-1500 20 mg, 40 mg, and EFV were studied at Stage 1. Optimal dose of VM-1500 was selected based on viral load at Week 12. Additional patients were enrolled at Stage 2 to demonstrate non-inferiority of VM-1500 vs. EFV.